For many cancer patients, diagnosis has traditionally meant surgery, painful tissue biopsies, and long waiting periods.
Today, hospitals across the Middle East are changing that experience. Instead of relying only on tissue samples, doctors are increasingly using liquid biopsy—a simple blood test that can detect tumor DNA, monitor treatment response, and identify genetic mutations without repeated invasive procedures.
As cancer cases continue to rise across the region, governments, hospitals, and diagnostic laboratories are investing in precision medicine to help patients receive faster and more personalized treatment.
Source: https://www.towardshealthcare.com/insights/middle-east-liquid-biopsy-market-sizing
Why Middle Eastern Countries Are Investing in Liquid Biopsy
Cancer is becoming one of the region’s biggest healthcare challenges.
According to the International Agency for Research on Cancer (IARC), the Gulf Cooperation Council (GCC) countries recorded 42,475 new cancer cases and nearly 19,900 cancer deaths in 2020.
Breast cancer remains the most common cancer, accounting for 16% of all new cases. Colorectal cancer follows at 13%, while thyroid cancer contributes around 9%.
Saudi Arabia alone represents nearly 65% of all cancer cases reported across the GCC, making advanced cancer diagnosis a national healthcare priority.
Instead of waiting until symptoms become severe, healthcare providers are focusing on detecting cancer earlier and tracking treatment more accurately through blood-based molecular testing.
The Hospitals and Labs Bringing Liquid Biopsy to Patients
Several leading healthcare organizations are expanding access to advanced genomic testing across the Middle East.
M42, one of the UAE’s largest healthcare and technology companies, operates more than 480 healthcare facilities through its network and manages one of the region’s largest genomic programs. In partnership with SOPHiA GENETICS and AstraZeneca, the company is helping hospitals use AI-powered genomic analysis to improve precision cancer care.
In Saudi Arabia, King Faisal Specialist Hospital & Research Centre (KFSHRC) has become one of the region’s leading precision medicine centers. The hospital performs advanced molecular diagnostics, genomic sequencing, and cancer biomarker testing for complex oncology cases while supporting national cancer research.
Another major player is King Abdullah International Medical Research Center (KAIMRC), which conducts genomic and cancer research to improve personalized treatment strategies across Saudi Arabia.
The Qatar Genome Program has also become one of the Middle East’s largest national genomics initiatives. The program has sequenced more than 30,000 whole genomes, creating valuable genetic data that helps researchers better understand inherited diseases and cancer in Arab populations.
Want to see the market opportunities, competitor strategies, and regional trends shaping your industry? Download a FREE customized sample report: https://www.towardshealthcare.com/download-sample/7011
Global Diagnostic Companies Are Powering Local Healthcare
Many hospitals across the Middle East rely on technology developed by global diagnostics companies.
Roche supplies molecular diagnostic systems and companion diagnostics used for cancer testing worldwide. The company generated CHF 60.5 billion (about US$74 billion) in revenue during 2025.
Thermo Fisher Scientific provides PCR instruments, next-generation sequencing systems, laboratory reagents, and oncology testing solutions. The company reported approximately US$43 billion in 2025 revenue.
Illumina, known for its DNA sequencing platforms used in precision oncology, generated around US$4.3 billion in revenue during 2025.
QIAGEN supports hospitals with sample preparation, molecular diagnostics, PCR technologies, and companion diagnostic solutions. The company recorded approximately US$2 billion in annual sales in 2025.
Guardant Health, a specialist in liquid biopsy, offers its Guardant360 blood test for comprehensive genomic profiling and reported approximately US$870 million in revenue during 2025. Its technologies are increasingly used by healthcare providers treating advanced cancer patients worldwide, including collaborations across the Middle East.
Government Programs Are Building the Future of Precision Medicine
Governments across the region are not only purchasing advanced equipment—they are creating long-term healthcare strategies.
Saudi Arabia established the Saudi Cancer Registry in 1992, and it now publishes nationwide cancer reports that help hospitals monitor disease trends and improve healthcare planning.
The UAE continues expanding genomic medicine through national precision healthcare initiatives, while Qatar has invested heavily in population genomics to support research and personalized medicine.
These programs are helping hospitals understand how cancer affects local populations and allowing doctors to select treatments based on a patient’s unique genetic profile rather than using the same approach for everyone.
Liquid Biopsy Is Becoming Part of Everyday Cancer Care
Liquid biopsy is no longer just a research technology.
Across Saudi Arabia, the UAE, Qatar, and other Middle Eastern countries, hospitals are using blood-based testing alongside traditional biopsies to help doctors diagnose cancer, monitor treatment, detect relapse, and identify targeted therapies.
As healthcare systems continue investing in genomic laboratories, digital pathology, and molecular diagnostics, patients are gaining access to faster, less invasive, and more personalized cancer care than ever before.
Middle East Liquid Biopsy at a Glance
| Indicator | Latest Data |
|---|---|
| New cancer cases in GCC (2020) | 42,475 |
| Cancer deaths in GCC (2020) | 19,895 |
| Breast cancer share | 16% |
| Colorectal cancer share | 13% |
| Thyroid cancer share | 9% |
| Saudi share of GCC cancer cases | ~65% |
| Qatar Genome Program genomes sequenced | 30,000+ |
| M42 healthcare facilities | 480+ |
| Roche 2025 revenue | CHF 60.5 billion |
| Thermo Fisher Scientific 2025 revenue | US$43 billion |
| Illumina 2025 revenue | US$4.3 billion |
| QIAGEN 2025 revenue | US$2.0 billion |
| Guardant Health 2025 revenue | US$870 million |
Access our exclusive, data-rich dashboard dedicated to the biotech industry – built specifically for decision-makers, strategists, and industry leaders. The dashboard features comprehensive statistical data, segment-wise market breakdowns, regional performance shares, detailed company profiles, annual updates, and much more. From market sizing to competitive intelligence, this powerful tool is one-stop solution to your gateway.
Access the Dashboard: https://www.towardshealthcare.com/access-dashboard
About Us
Healthcare WebWire is a part of Towards Healthcare Research and Consulting is a global strategy and intelligence firm focused on the biotechnology sector. We partner with biotech companies and research organizations to support innovation across drug discovery, bioprocessing, and advanced therapeutics. Through deep scientific insight and market analytics, we help accelerate development timelines, optimize R&D strategies, and translate breakthrough science into commercially viable solutions.
You can place an order or ask any questions, please feel free to contact us at [email protected]
Europe Region – +44 778 256 0738
North America Region – +1 8044 4193 44
APAC Region: +91 9356 9282 04
Visit Our Website: https://www.towardshealthcare.com
Find us on social platforms: LinkedIn | Twitter | Instagram | Medium